OXB Launches New Brand Identity to Showcase Transformation
OXB, the new name for Oxford Biomedica, has rolled out an exciting rebranding effort designed to reinforce its status as a top-tier global contract development and manufacturing organization (CDMO) focused on cell and gene therapy. This fresh identity not only brings a modern visual appeal but also highlights OXB's dedication to innovation and technical excellence in the field.
A Global Authority in Cell and Gene Therapy
The transition to OXB marks a pivotal moment in the company’s journey. As a major player in the cell and gene therapy arena, OXB is known for its unwavering commitment to providing high-quality solutions throughout every aspect of viral vector development and manufacturing. This new branding reflects OXB's distinct approach, which combines agile execution and creativity to fulfill the various aims of its clients.
CEO's Thoughts on the Rebranding
Dr. Frank Mathias, OXB's Chief Executive Officer, offered his perspective on the newly unveiled brand identity. He remarked, "The introduction of our new brand identity underscores OXB's remarkable transformation into a leading pure-play CDMO for cell and gene therapy. This rebranding represents much more than just a visual update; it embodies the global nature of our operations and our strong commitment to advancing our clients’ drug development initiatives." With enhanced capabilities and a worldwide presence, OXB is well-equipped to strengthen its collaborations with clients, guiding them from initial development to commercial-scale manufacturing.
Dedication to High-Quality Therapeutic Solutions
OXB brings over 25 years of expertise in viral vector development, partnering with top pharmaceutical and biotechnology firms to deliver exceptional viral vector manufacturing services. The company's know-how includes several types of viral vectors, such as lentivirus, adeno-associated virus (AAV), and adenovirus. Thanks to its robust quality assurance systems and regulatory know-how, OXB ensures clients receive cutting-edge, tailored solutions that meet their specific requirements.
Innovative Manufacturing Technologies from OXB
OXB uniquely stands out with its cutting-edge technologies for viral vector production, featuring advanced systems like Tetravecta™, a 4th generation lentiviral vector system. This innovative technique, alongside other advancements such as dual plasmid systems for AAV production, positions OXB as a leader in scientific progress within the industry.
Global Reach and Future Aspirations
With its headquarters in Oxford, UK, OXB operates top-notch bioprocessing and manufacturing facilities across several locations, including Oxfordshire, Lyon, Strasbourg, and near Boston, MA. This international footprint enables OXB to provide comprehensive services aligned with the changing needs of its clients, positioning the company as an essential partner in the biotherapeutics landscape.
Focus on Client Success
OXB’s dedication to client success is evident not only in its operational strengths but also in its commitment to ethical standards and a collaborative culture. By prioritizing accountability and professionalism, OXB fosters meaningful partnerships, working side by side with clients to drive their drug development projects forward, ultimately bringing transformative therapies to patients around the world.
Frequently Asked Questions
What does the rebranding from Oxford Biomedica to OXB signify?
The rebranding indicates OXB's growth into a leading pure-play cell and gene therapy CDMO, highlighting its focus on innovation and high-quality therapeutic solutions.
How long has OXB been in the field of cell and gene therapy?
With over 25 years of experience in viral vector development, OXB has been a trailblazer in the realm of cell and gene therapy.
Which types of viral vectors does OXB focus on?
OXB specializes in an array of viral vectors, particularly lentivirus, adeno-associated virus (AAV), and adenovirus.
What manufacturing technologies are offered by OXB?
OXB provides a variety of innovative technologies, including the Tetravecta™ system for lentiviral vectors and dual plasmid systems for AAV production.
Where are OXB's manufacturing facilities situated?
OXB has manufacturing locations in the UK, France, and near Boston, MA, giving the company a substantial global presence for its operations.
